BMRN
NASDAQ · Biotechnology
Biomarin Pharmaceutical Inc
$56.12
-1.01 (-1.77%)
Performance
1D
—
1W
-4.08%
1M
+1.67%
3M
-18.52%
6M
+6.73%
1Y
+8.26%
YTD
-5.60%
Open$57.44
Previous Close$57.13
Day High$57.99
Day Low$55.97
52W High$70.98
52W Low$49.26
Volume—
Avg Volume2.51M
Market Cap11.23B
P/E Ratio153.86
EPS$0.36
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$60.06
Below
SMA 200
$58.46
Below
RSI (14)
53.7
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
35 analysts
Price Target
+125.3% upside
Current
$56.12
$56.12
Target
$126.44
$126.44
$89.21
$126.44 avg
$194.19
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.13B | 2.71B | 1.41B |
| Net Income | 339.16M | 264.51M | -2,303,166 |
| Profit Margin | 10.8% | 10.3% | -0.2% |
| EBITDA | 416.89M | 343.20M | -4,073,088 |
| Free Cash Flow | — | — | -1,983,877 |
| Rev Growth | +15.4% | +15.4% | -7.9% |
| Debt/Equity | 0.10 | 0.10 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |